MX357521B - 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS. - Google Patents
2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS.Info
- Publication number
- MX357521B MX357521B MX2013002612A MX2013002612A MX357521B MX 357521 B MX357521 B MX 357521B MX 2013002612 A MX2013002612 A MX 2013002612A MX 2013002612 A MX2013002612 A MX 2013002612A MX 357521 B MX357521 B MX 357521B
- Authority
- MX
- Mexico
- Prior art keywords
- amyloidopathy
- cerebral
- prediagnosis
- synucleopathy
- piperazin
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| PCT/EP2011/064893 WO2012031941A2 (de) | 2010-09-07 | 2011-08-30 | 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013002612A MX2013002612A (es) | 2013-08-01 |
| MX357521B true MX357521B (es) | 2018-07-12 |
Family
ID=44645670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002612A MX357521B (es) | 2010-09-07 | 2011-08-30 | 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (enExample) |
| EP (3) | EP2693216B1 (enExample) |
| JP (2) | JP6084924B2 (enExample) |
| CN (2) | CN106243060A (enExample) |
| BR (1) | BR112013005472A2 (enExample) |
| CA (2) | CA2870626C (enExample) |
| DE (2) | DE102010062810B4 (enExample) |
| DK (2) | DK2614060T3 (enExample) |
| ES (2) | ES2605705T3 (enExample) |
| MX (1) | MX357521B (enExample) |
| PL (2) | PL2614060T3 (enExample) |
| RU (2) | RU2016118021A (enExample) |
| WO (1) | WO2012031941A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| BR112021000802A2 (pt) | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| WO2021188457A1 (en) * | 2020-03-16 | 2021-09-23 | Doublerainbow Biosciences Inc. | Etoposide glycosides, methods of making, and uses thereof as an anti-cancer drug |
| JP7897954B2 (ja) * | 2022-01-04 | 2026-07-30 | イムヌジェネティクス アーゲー | アルツハイマー型認知症の処置又は予防における使用のための特定の投与量のフェノチアジン化合物 |
| EP4605754A1 (en) * | 2022-10-18 | 2025-08-27 | Immungenetics AG | Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (enExample) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| EP1470818B1 (en) * | 2003-04-25 | 2006-07-26 | Neuro3D | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| MY162313A (en) * | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| JP5244810B2 (ja) * | 2006-11-10 | 2013-07-24 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミド |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| MX2010011880A (es) * | 2008-04-29 | 2011-05-25 | Pharnext | Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular. |
| NZ589307A (en) * | 2008-04-29 | 2012-04-27 | Pharnext | Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| US9399032B2 (en) * | 2009-05-14 | 2016-07-26 | The General Hospital Corporation | Methods and compositions for treating degenerative and ischemic disorders |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490029A1 (ru) | Соединения, ингибирующие металлоферменты | |
| ATE458732T1 (de) | Verwendung von 4-imidazol-derivaten für zns- erkrankungen | |
| CY1121981T1 (el) | Μεθοδος για τον προσδιορισμο κινδυνου pml | |
| EP2635187A4 (en) | IMPROVED ALGORITHM FOR THE DETECTION OF DIABETES | |
| SI3448035T1 (sl) | Postopek za izvajanje notranjega napovedovanja z uporabo adaptivnega filtra | |
| EP2504702A4 (en) | DEVICES FOR DETECTION OF COMPOUNDS FOR ANALYZING | |
| CR20170001A (es) | Anticuerpos anti factor d humanizados | |
| EP2611829A4 (en) | NOVEL ANTIGEN BINDING PROTEINS | |
| EA201300583A1 (ru) | Вазопротективное и кардиопротективное противодиабетическое лечение | |
| SMT201400072B (it) | Nuovi composti utili per il trattamento di malattie degenerative e infiammatorie | |
| ATE550333T1 (de) | 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| EP2916860A4 (en) | COMPOSITION FOR THE TREATMENT OF DIABETES OR OBESITAS-CONDITIONING DIABETES WITH AN OXYNTOMODULIN ANALOG | |
| BRPI0923359A2 (pt) | Anticorpos anti-igf | |
| EP2648793A4 (en) | INTEGRATED SYSTEM FOR TESTING WATER FLUID | |
| WO2011112687A3 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| IL207193A0 (en) | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta | |
| DK2368118T3 (da) | Biomarkører til inhibitorer med anti-angiogen aktivitet | |
| BRPI0922055A2 (pt) | correia de sustentação de instalação de elevador. | |
| BRPI1011805A2 (pt) | anticorpos anti incisura-1 | |
| MX2013002612A (es) | 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS. | |
| ATE511657T1 (de) | Bestimmungsverfahren für equine nt-probnp. | |
| FR2980271B1 (fr) | Procede de determination de la glycosylation d'un anticorps | |
| EP2358200A4 (en) | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | |
| MY154715A (en) | Anti-nr10 antibody and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: IMMUNGENETICS AG |
|
| FG | Grant or registration |